Siemens Healthcare Diagnostics has developed a fully automated sex hormone binding globulin (SHBG) immunoassay for testing plasma or serum samples on the Advia Centaur platform.
A free prostate-specific antigen (fPSA) assay for use on the Advia Centaur and Advia Centaur XP systems is also available.
The SHBG assay completes the fertility panel on the Advia Centaur family of analysers to offer a comprehensive range of testing capabilities.
It provides accurate results in the evaluation of androgen disorders including virilisation, hirsutism and polycystic ovary syndrome and enables the determination of the free androgen index by automatically calculating the ratio of testosterone to SHBG.
The assay has a short time to first result, sound compatibility with WHO standard 95/560 and good within-run and between-run precision.
The Advia Centaur fPSA assay has been developed for use with the Advia Centaur Total PSA assay to assist in differentiating between prostate cancer and benign prostatic disease.
Suitable for men aged 50 and above, with total PSA values between 4-10ug/L and Digital Rectal Exam (DRE) non-suspicious for cancer, the assay determines the percent free PSA value.
The assay has a turnaround time of 18mins, good within-run precision to ensure accurate monitoring and a reagent on-board stability of 60 days.
